Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
09/2005
09/20/2005CA2189882C Papillomavirus vaccines
09/20/2005CA2170606C Type i angiotensin ii receptor specific monoclonal antibodies and hybridomas
09/15/2005WO2005085867A2 Screening method for emulators of neural activity and digestive system using gpr35
09/15/2005WO2005085861A2 Nucleic acids and encoded polypeptides for use in liver disorders and epithelial cancer
09/15/2005WO2005085846A1 Diagnostic for ischemic heart disease risk group
09/15/2005WO2005085323A2 Methods and compositions for treatment of autoimmune diseases
09/15/2005WO2005085287A1 Treatments for contaminant reduction in lactoferrin preparations and lactoferrin-containing compositions
09/15/2005WO2005085283A1 Modified interleukin-11 and medicinal composition containing the same
09/15/2005WO2005085282A1 Il-15 binding site for il15-ralpha and specific il-15 mutants having agonists/antagonists activity
09/15/2005WO2005085281A1 Mutein of a bone morphogenetic protein and use thereof
09/15/2005WO2005085280A2 HUMAN cDNA CLONES COMPRISING POLYNUCLEOTIDES ENCODING POLYPEPTIDES AND METHODS OF THEIR USE
09/15/2005WO2005085278A1 Fusion proteins comprising modified allergens of the ns-ltps family, use thereof and pharmaceutical compositions comprising the same
09/15/2005WO2005085276A1 A novel potassium channel modulator peptide
09/15/2005WO2005085275A1 Inhibitors of hepatitis c virus ns3 protease
09/15/2005WO2005085242A1 Novel ketoamides with cyclic p4's as inhibitors of ns3 serine protease of hepatitis c virus
09/15/2005WO2005085236A2 Caspase inhibitors and uses thereof
09/15/2005WO2005085210A1 Nitriles and medicinal compositions containing the same as the active ingredient
09/15/2005WO2005084714A2 Raav-neprilysin compositions and methods of use
09/15/2005WO2005084710A2 Nanocell drug delivery system
09/15/2005WO2005084705A1 Botulinum toxin treatments of neurological and neuropsychiatric disorders
09/15/2005WO2005084704A1 Digestive bypass composition for arthropod and uses thereof
09/15/2005WO2005084703A1 Sustained-release composition for oral cavity
09/15/2005WO2005084702A1 Agent for preventing and treating organ fibrosis
09/15/2005WO2005084701A1 Combination of morphogenic proteins having tissue inductive properties
09/15/2005WO2005084700A1 An agent for promoting induction of vascular differentiation, comprising hepatocyte growth factor
09/15/2005WO2005084699A1 Alk7 and myostatin inhibitors and uses thereof
09/15/2005WO2005084698A1 A diffenrentiation- or regeneration-inducing agent for alveoli
09/15/2005WO2005084697A1 Regulator for adiponectin receptor expression
09/15/2005WO2005084696A1 Methods and agents for controlling intestinal inflammation and mucosal immunity using agents interacting with tir8/sigirr
09/15/2005WO2005084695A2 Use of carboxypeptidase g for combating antifolate toxicity
09/15/2005WO2005084694A1 Influenza virus-infection inhibitor
09/15/2005WO2005084690A1 Use of enhanced water to improve blood sugar management
09/15/2005WO2005084684A1 Use of a mixture for the production of an agent for treating defective or degenerated cartilage in the production of natural cartilage replacement in vitro
09/15/2005WO2005084681A1 Composition for increasing levels of hormones and a method for preparation of said composition
09/15/2005WO2005084652A2 Use of antagonists of the cb1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases
09/15/2005WO2005084646A1 Powdered compositions of sensitive active materials in an at least partially amorphous state
09/15/2005WO2005084642A1 Apoprotein cochleate compositions
09/15/2005WO2005084625A1 Method and composition for treating oral bacteria and inflammation
09/15/2005WO2005084612A1 The new usage of elastase inhibitors
09/15/2005WO2005084444A1 Compositions and methods for the treatment and clinical remission of psoriasis
09/15/2005WO2005084307A2 Use of lipid conjugates in the treatment of disease
09/15/2005WO2005084301A2 Compositions and methods for treating diseases
09/15/2005WO2005084210A2 Multiplex detection probes
09/15/2005WO2005084198A2 Peptides of il1 beta and tnf alpha and method of treatment using same
09/15/2005WO2005067958A3 Methods and compositions for the inhibition of cathepsins
09/15/2005WO2005058351A3 Treatment of rheumatoid arthritis with soluble fas-ligand cross-linkers
09/15/2005WO2005054430A3 Hepatitis c virus inhibitors
09/15/2005WO2005054284A3 Regulation involving abin-2
09/15/2005WO2005051421A3 Use of shigella invaplex to transport functional proteins and transcriptionally active nucleic acids across mammalian cell membranes in vitro and in vivo
09/15/2005WO2005049084A3 Inhibition of trp channels as a treatment for cardiac hypertrophy and heart failure
09/15/2005WO2005047316A3 Insulin releasing peptides
09/15/2005WO2005046711A3 Stimulation or inhibition of gamma delta t-cells to promote or inhibit bone healing
09/15/2005WO2005044982A3 Monomeric recombinant mhc molecules useful for manipulation of antigen-specific t cells
09/15/2005WO2005044306A3 Use of antagonist anti-cd40 antibodies for treatment of autoimmune and inflammatory diseases and organ transplant rejection
09/15/2005WO2005044294A3 Method of therapy for cancers expressing the cd40 antigen
09/15/2005WO2005042568A3 Hydrochloride salts of a glycopeptide phosphonate derivative
09/15/2005WO2005040802A3 Cylin binding peptides, and their use in drug screening assays
09/15/2005WO2005040195A3 Formulation of exendins
09/15/2005WO2005026323A3 Stationary phases and a purification process using the stationary phases
09/15/2005WO2005023837A3 Ebola peptides and immunogenic compositions containing same
09/15/2005WO2005016256A3 Hemostatic compositions containing sterile thrombin
09/15/2005WO2005004895A3 Compositions and methods for enhanced mucosal delivery of growth hormone
09/15/2005WO2005003347A3 Dna-based aptamers for human cathepsin g
09/15/2005WO2005000895A3 Vegf traps and therapeutic uses thereof
09/15/2005WO2004111086A3 Peptide analogues comprising at least one type of aminoacyl aza-$g(b)3 and the use thereof, in particular for therapy
09/15/2005WO2004094472A3 Collagen fibrils carrying bioactive heterologous domains and their use in e.g. wound healing
09/15/2005WO2004094461A3 Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
09/15/2005WO2004085461A3 Tumour-associated peptides binding to mhc molecules
09/15/2005WO2004084711A3 Methods of detecting neurological disorders
09/15/2005WO2004073644A3 Water-soluble silk proteins in compositions for skin care, hair care or hair coloring
09/15/2005WO2004056307A3 Disease treatment via antimicrobial peptide inhibitors
09/15/2005WO2004050832A3 Antimicrobial compounds from bacillus subtilis for use against animal and human pathogens
09/15/2005WO2004047771A3 Peptides which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, compositions and uses thereof
09/15/2005WO2004020586A3 Beta-2 microglobulin (b2m) and b2m related gene products for the regulation of osteoarthritis pathogenesis and chondrocyte proliferation
09/15/2005WO2004015078A3 Methods and materials relating to novel growth regulatory-like polypeptides and polynucleotides
09/15/2005WO2004013288A3 Methods and kits for synthesis of sirna expression cassettes
09/15/2005WO2004009112A8 Use of urease for inhibiting cancer cell growth
09/15/2005WO2003106657A3 Wise/sost nucleic acid sequences and amino acid sequences
09/15/2005WO2003020881A3 DOMINANT NEGATIVE VARIANTS OF METHIONINE AMINOPEPTIDASE 2 (MetAP2) AND CLINICAL USES THEREOF
09/15/2005WO2003000844A3 Protein modification and maintenance molecules
09/15/2005WO2002094407A3 Protein fractionation and single p0lymer matrix unit chromatography
09/15/2005WO2002048388A3 Method of inhibiting infection by hcv, other flaviviridae viruses, and any other virus that complexes to low density lipoprotein or to very low density lipoprotein in blood preventing viral entry into a cell
09/15/2005US20050204415 Methods of blocking tissue destruction by autoreactive T cells
09/15/2005US20050204414 Methods of blocking tissue destruction by autoreactive T cells
09/15/2005US20050204413 Methods of blocking tissue destruction by autoreactive T cells
09/15/2005US20050204412 Artery- and vein-specific proteins and uses therefor
09/15/2005US20050204411 Expression vector comprising nucleotide sequences coding blood coagulation factor for use as heterologous gene expression tool; treating blood disorders; bioreactor for producing secreted proteins
09/15/2005US20050204406 Expression vector comprising nucleotide sequences coding blood coagulation factor for use as heterologous gene expression tool; treating blood disorders; bioreactor for producing secreted proteins
09/15/2005US20050203635 Soft tissue implants and anti-scarring agents
09/15/2005US20050203295 NO donor has a nitroso group attached to a tertiary carbon; vascular relaxants, nonsteroidal anti-inflammatory drug; water soluble; potentiated by adding glutathione, use low dosage
09/15/2005US20050203288 Amino acid sequences which suppress the activities of inhibitors of apoptosis proteins (IAPs); for use as tool in treatment of cell proliferative disorders
09/15/2005US20050203284 a 15 to 22-residue polypeptide analog that forms an amphipathic alpha helix in the presence of lipids; anticholesterol agents; hypercholesterolemia, cardiovascular disorders, atherosclerosis, restenosis, hypertriglyceridemia, high density lipoprotein deficiency, metabolic disorders
09/15/2005US20050203282 For screening of agonists and antagonists of receptor which may have advantageous pharmaceutical or diagnostical properties; for identification of patients who may present genetic disorders induced by inactive receptor
09/15/2005US20050203281 Generating insoluble matrices comprising immobilized nicotinic acetylcholine receptor (AChR) for use as tool in diagnosing myasthenia gravis; immunodiagnostics
09/15/2005US20050203166 Indole-3-acetic acid derivatives
09/15/2005US20050203165 Perfectly reproducible crystalline form that especially exhibits valuable characteristics for formulation of inhibitors of angiotensin I converting enzyme; preparation from a solution of the salt in CH2Cl2 or ethyl acetate; treating cardiovascular disease
09/15/2005US20050203152 Polymorph of a pharmaceutical
09/15/2005US20050203093 Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4
09/15/2005US20050203080 Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
09/15/2005US20050203054 Use of lipid conjugates in the treatment of diseases
1 ... 1378 1379 1380 1381 1382 1383 1384 1385 1386 1387 1388 1389 1390 1391 1392 1393 1394 1395 1396 1397 1398 ... 3163